Silence Therapeutics Announces Topline 36-Week Data From Ongoing Phase 2 Study of Zerlasiran in Patients With High Lipoprotein(a)
Silence Therapeutics Announces Topline 36-Week Data From Ongoing Phase 2 Study of Zerlasiran in Patients With High Lipoprotein(a)
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein(a), or Lp(a), levels at or over 125 nmol/L at high risk of atherosclerotic cardiovascular disease (ASCVD) events. Zerlasiran is a siRNA (short interfering RNA) designed to lower the body's production of Lp(a), a key genetic risk factor for cardiovascular disease affecting up to 20% of the world's population.
Silence Therapeutics plc，納斯達克：SLN（“Silence” 或 “公司”）是一家經驗豐富、創新的生物技術公司，致力於通過精密工程藥物消滅疾病來改變人們的生活。該公司今天公佈了正在進行的針對澤拉西蘭（SLN360）的 178 名基線脂蛋白（a）或 Lp（a）水平等於或大於 125 nmol/L 的受試者的 36 周積極數據動脈粥樣硬化性心血管疾病（ASCVD）事件的高風險。ALPACAR-360Zerlasiran是一種siRNA（短干擾RNA），旨在降低人體產生Lp（a），Lp（a）是影響全球多達20％人口的心血管疾病的關鍵遺傳危險因素。
譯文內容由第三人軟體翻譯。